mRNA vaccines (such as those for Covid) are typically administered into the deltoid muscle of the upper arm. Relating to investigations into long-covid symptoms potentially induced by both the natural infection and specifically mRNA variants of the vaccine, questions can be raised and investigated relating to the proliferation, diffusion and binding of the Covid spike protein after entering the bloodstream, however this extends to any protein synthesised via mRNA vaccines.
- Can synthesised proteins transition from deltoid muscle tissue and diffuse into the bloodstream?
- If so, how much can diffuse into the bloodstream, and what factors in the application method affect this diffusion amount / rate?
- Once in the bloodstream, what is the potential for proteins to reach any particular region of the body?
- For each protein, what is the binding potential in any particular area of the body?
- Is there a potential for endocrinological or immune activation, or organ system behavioural changes in response to binding of the particular protein.
- Covid-specific: Can the spike protein from an mRNA vaccine diffuse into the bloodstream and subsequently bind with ACE2 receptors on carotid bodies, affecting perception of blood oxygen?
- Covid-specific: Can the spike protein from an mRNA vaccine diffuse into the bloodstream and induce mast cell degranulation behaviours in other regions of the body?
- Covid-specific: Can the spike protein from an mRNA vaccine diffuse into the bloodstream and bind to ACE2 receptors in the endothelial regions of blood vessels?
- If so, are there any measurable symptoms or disease pathologies that may occur, and are there any particular vessels / organ systems more likely to be affected than others?
Curtis Holt - Studio / Lab 